Evidence map›Paper›PMID 27084738›Full record

ReviewClinical cancer research : an official journal of the American Association for Cancer Research2016

Emerging Opportunities and Challenges in Cancer Immunotherapy.

Theresa L Whiteside, Sandra Demaria, Maria E Rodriguez-Ruiz, Hassane M Zarour, Ignacio Melero

2 registry-linked trialsOpen access · bronzeAbstract readReview
In one paragraph

Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 171 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
171citing papers in PubMed, 2 pooled it
15.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03792724 phase1 / phase2unknown statusnot on this mapstarted 2019, after this paper: background citation

Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors

TypeinterventionalSponsorClinica Universidad de Navarra, Universidad de NavarraRan2019 to 2023Enrolled32ConditionsNeoplasmsArmsUrelumab + Nivolumab
NCT05504252 phase2active not recruitingnot on this mapstarted 2022, after this paper: background citation

METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin

TypeinterventionalSponsorUniversity Hospital, AkershusRan2022 to 2028Enrolled80ConditionsColorectal Adenocarcinoma, Mucinous Adenocarcinoma, Signet Ring Cell AdenocarcinomaArmsNivolumab, Oxaliplatin
3 · Its place in the literature

Who cites it

171 citing papers in PubMed, 2 syntheses or guidelines pooled it, 310 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017
    Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Battlegrounds of treatment resistance: decoding the tumor microenvironment.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  15. Review
  16. Review
  17. Article
  18. Lymph node-targeted delivery ofMaterials today. Bio · 2025
    Article
  19. Article
  20. Review

111 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Theresa L WhitesideDepartment of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Sandra DemariaDepartment of Radiation Oncology, University of Cornell, New York, New York.
Maria E Rodriguez-RuizCenter for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain. Clinica Universidad de Navarra, Pamplona, Spain.
Hassane M ZarourDepartment of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Ignacio MeleroCenter for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain. Clinica Universidad de Navarra, Pamplona, Spain. imelero@unav.es.
Clinica Universidad de Navarra · ES

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0M
Therapuetic Immune Targeting of EphA2 Expressed by Melanoma & Its Tumor-AssociateP50CA121973 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KIRKWOOD, JOHN MUNN · 2008 to 2018
$22.9M
Cancer Cell Intrinsic Interferon-I pathway Activation by Fractionated RadiationR01CA201246 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI DEMARIA, SANDRA · 2016 to 2025
$3.9M
Restoring anti-tumor immunity in the microenvironment of head and neck cancerR01CA168628 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WHITESIDE, THERESA L. · 2013 to 2017
$1.7M
Reversing melanoma-induced T cell dysfunctionR01CA157467 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZAROUR, HASSANE M · 2011 to 2015
$1.5M
NCI NIH HHS P30 CA047904NCI NIH HHS P30CA047904NCI NIH HHS P50 CA121973NCI NIH HHS P50CA121973NCI NIH HHS R01 CA157467NCI NIH HHS R01CA157467NCI NIH HHS R01CA16862NCI NIH HHS R01 CA168628NCI NIH HHS R01 CA201246NCI NIH HHS R01CA201246
6 · The paper itself

Abstract

Immunotherapy strategies against cancer are emerging as powerful weapons for treatment of this disease. The success of checkpoint inhibitors against metastatic melanoma and adoptive T-cell therapy with chimeric antigen receptor T cells against B-cell-derived leukemias and lymphomas are only two examples of developments that are changing the paradigms of clinical cancer management. These changes are a result of many years of intense research into complex and interrelated cellular and molecular mechanisms controling immune responses. Promising advances come from the discovery of cancer mutation-encoded neoantigens, improvements in vaccine development, progress in delivery of cellular therapies, and impressive achievements in biotechnology. As a result, radical transformation of cancer treatment is taking place in which conventional cancer treatments are being integrated with immunotherapeutic agents. Many clinical trials are in progress testing potential synergistic effects of treatments combining immunotherapy with other therapies. Much remains to be learned about the selection, delivery, and off-target effects of immunotherapy used alone or in combination. The existence of numerous escape mechanisms from the host immune system that human tumors have evolved still is a barrier to success. Efforts to understand the rules of immune cell dysfunction and of cancer-associated local and systemic immune suppression are providing new insights and fuel the enthusiasm for new therapeutic strategies. In the future, it might be possible to tailor immune therapy for each cancer patient. The use of new immune biomarkers and the ability to assess responses to therapy by noninvasive monitoring promise to improve early cancer diagnosis and prognosis. Personalized immunotherapy based on individual genetic, molecular, and immune profiling is a potentially achievable future goal. The current excitement for immunotherapy is justified in view of many existing opportunities for harnessing the immune system to treat cancer.

Indexed as

ImmunotherapyAnimalsAntibodies, MonoclonalAntineoplastic AgentsCombined Modality TherapyHumansImmunomodulationMolecular Targeted TherapyNeoplasmsT-Lymphocyte SubsetsTumor MicroenvironmentAntibodies, MonoclonalAntineoplastic Agents

Identifiers

PMID27084738
PMCPMC4943317
OpenAlexW2340751952

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.